Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $27.13.

KURA has been the topic of several research analyst reports. JMP Securities restated a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. HC Wainwright boosted their target price on Kura Oncology from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Finally, BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th.

Insiders Place Their Bets

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Barclays PLC grew its stake in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Kura Oncology in the 4th quarter worth $436,000. Moody Aldrich Partners LLC grew its position in Kura Oncology by 42.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after purchasing an additional 42,712 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after purchasing an additional 2,076 shares during the period. Finally, Jennison Associates LLC acquired a new position in shares of Kura Oncology during the fourth quarter valued at about $623,000.

Kura Oncology Stock Performance

Shares of KURA opened at $7.88 on Tuesday. The company has a market capitalization of $612.78 million, a PE ratio of -3.34 and a beta of 0.78. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company’s 50 day moving average price is $8.26 and its 200 day moving average price is $14.04. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.